MedTrace Logo

Phase II Trial of RC1416 Injection in Asthma

NCT07403487 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 195

Last updated 2026-02-11

No results posted yet for this study

Summary

This study is a phase II study of RC1416 in subjects with severe uncontrolled asthma. The purpose of the study is to evaluate efficacy and safety of RC1416 in subjects with severe uncontrolled asthma.

Conditions

  • Moderate to Severe Asthma

Interventions

DRUG

RC1416

There are two doses in this part. Each subjects will receive the drug by subcutaneous injection.

DRUG

RC1416 Placebo

Each subjects will receive the placebo by subcutaneous injection

Sponsors & Collaborators

  • Nanjing RegeneCore Biotech Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-10
Primary Completion
2027-10-25
Completion
2028-02-28
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07403487 on ClinicalTrials.gov